Greenspring Advisors LLC Invests $370,000 in Danaher Co. (NYSE:DHR)

Greenspring Advisors LLC purchased a new position in Danaher Co. (NYSE:DHR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,331 shares of the conglomerate’s stock, valued at approximately $370,000.

Other hedge funds have also recently made changes to their positions in the company. Benjamin Edwards Inc. grew its holdings in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC grew its holdings in shares of Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after buying an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. grew its holdings in shares of Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after buying an additional 40 shares in the last quarter. Trust Co of Kansas grew its holdings in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after buying an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. grew its holdings in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after buying an additional 40 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Down 1.1 %

Shares of DHR opened at $245.39 on Monday. The stock has a market capitalization of $181.76 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company’s 50-day simple moving average is $269.52 and its 200-day simple moving average is $260.53.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 earnings per share. Analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DHR. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. UBS Group dropped their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Raymond James dropped their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Barclays dropped their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.